← Browse by Condition
Medical Condition

gvhd

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for gvhd sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — gvhd Clinical Trials

How many clinical trials are currently recruiting for gvhd?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for gvhd, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for gvhd?
gvhd research spans Phase 1 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a gvhd clinical trial?
Eligibility criteria for gvhd trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
University Hospital Pilsen 1 trial
Stanford University 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial

Recruiting Clinical Trials

NCT07570407
Recruiting
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
Enrollment
75 pts
Location
Czechia
Sponsor
University Hospital Pilsen
View Trial →
NCT07302776 Phase 1
Recruiting
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Enrollment
50 pts
Location
United States
Sponsor
Stanford University
View Trial →
NCT06083129 Phase 3
Recruiting
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Enrollment
324 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →

Related Conditions

allogeneic hsct (1) posttransplant complications (1) relapse (1) acute myeloid leukemia (1) hematopoietic cell transplantation hct (1) acute myeloid leukemia aml (1) myelodysplastic syndromes (1) myelofibrosis mf (1) chronic myeloid leukemia cml (1) chronic myelomonocytic leukemia cmml (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology